Business Context and Reporting Period
Sunshine Biopharma Inc. filed this Form 8-K on November 14, 2014, to report the entry into a Material Definitive Agreement. The company, incorporated in Colorado with principal offices in Montreal, Canada, is a small business issuer focused on the development of anticancer drugs.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial figure disclosed relates to the new agreement:
- Estimated Agreement Cost: 145,550 CHF (approximately $139,700 USD).
Material Changes
The primary material change is the execution of a Manufacturing Services Agreement with Lonza Ltd. and Lonza Sales Ltd. (collectively "Lonza") on November 14, 2014, effective November 10, 2014. Key terms include:
- Scope: Lonza will manufacture Sunshine Biopharma's Adva-27a anticancer drug for clinical supply and commercialization.
- Capacity: Manufacturing capabilities range from grams to tons scale.
- Duration: The agreement has a 5-year term with provisions for extension or earlier termination.
- Timeline: Delivery of the initial batch for product validation is expected 18 weeks after receipt of the Purchase Order.
- Compliance: Manufacturing will adhere to current Good Manufacturing Practices (cGMP) for the U.S., Europe, and other agreed jurisdictions.
Outlook, Risks, and Management Commentary
Management highlights Lonza's expertise and worldwide reputation in medical product development. The agreement facilitates the creation of a master drug file for regulatory filing to secure ultimate drug approval. Kilogram-level cGMP manufacturing for clinical trials will commence after the initial validation batch is completed and tested.
Risks and Contingencies:
- Quality Control: While Lonza is responsible for procuring raw materials, quality assurance is a shared responsibility. Sunshine Biopharma retains the right to inspect, test, and approve all batches within 30 days of release.
- Dispute Resolution: Disputes regarding manufacturing specifications will be resolved through independent analysis and testing.
- Operational Oversight: The company will maintain one representative at the Lonza facility during the manufacturing process.
Investor Verification Checklist
- Verify the total capital requirements to fund the estimated $139,700 USD initial cost and subsequent manufacturing batches.
- Confirm the timeline for the initial product validation batch delivery relative to the Purchase Order date.
- Review the attached Press Release (Exhibit 99.5) for additional details on the strategic partnership.
- Assess the company's cash position to ensure liquidity for the 5-year agreement term.